OmniaBio Revenue and Competitors
Estimated Revenue & Valuation
- OmniaBio's estimated annual revenue is currently $13.5M per year.
- OmniaBio's estimated revenue per employee is $99,889
Employee Data
- OmniaBio has 135 Employees.
- OmniaBio grew their employee count by 59% last year.
OmniaBio's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Executive Assistant To CEO | Reveal Email/Phone |
3 | Chief Legal Officer | Reveal Email/Phone |
4 | Chief Commercial Officer | Reveal Email/Phone |
5 | VP, Supply Chain | Reveal Email/Phone |
6 | Director, Business Development | Reveal Email/Phone |
7 | Director, Business Development | Reveal Email/Phone |
8 | Associate Director, MSAT | Reveal Email/Phone |
9 | Director Commercial Operations | Reveal Email/Phone |
10 | Associate Director | Reveal Email/Phone |
OmniaBio Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | N/A | 22 | 29% | $5M | N/A |
#2 | N/A | 9 | 29% | N/A | N/A |
#3 | $0.7M | 9 | -72% | $39.4M | N/A |
#4 | $0.9M | 11 | -83% | $23.8M | N/A |
#5 | $87.6M | 499 | 8% | N/A | N/A |
#6 | $2.8M | 18 | 13% | N/A | N/A |
#7 | $7.8M | 50 | -68% | N/A | N/A |
#8 | $13.5M | 96 | 30% | N/A | N/A |
#9 | $17.8M | 115 | -6% | N/A | N/A |
#10 | $0.9M | 11 | -39% | N/A | N/A |
What Is OmniaBio?
OmniaBio Inc., a subsidiary of CCRM, launched July 1, 2022. OmniaBio is a contract development and manufacturing organization (CDMO) conducting process development and producing gene-modified cells and viral vectors for Phase I clinical trials to commercial-scale manufacturing. OmniaBio is bringing life-saving cell and gene therapies to patients in Canada and around the world.
keywords:N/AN/A
Total Funding
135
Number of Employees
$13.5M
Revenue (est)
59%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | N/A | 136 | 28% | N/A |
#2 | N/A | 138 | 21% | N/A |
#3 | $28.5M | 141 | -7% | N/A |
#4 | $35M | 144 | -3% | N/A |
#5 | $44.8M | 144 | 8% | N/A |